Chemomab Therapeutics Ltd DRC (CMMB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $12.31M
Last updated: Nov 17, 2026 at 4:04 PM ET
Chemomab Therapeutics Ltd DRC (CMMB) Statistics
Chemomab Therapeutics Ltd DRC (CMMB) has a market cap of $12.31M and an enterprise value of $6.32M. Its share count is up 38.13% from a year earlier. It holds $6.00M more cash than debt, 48.71% of its market cap.
Total Valuation
Enterprise value is 48.71% below the market cap, as cash exceeds debt.
| Market Cap | $12.31M |
|---|---|
| Enterprise Value | $6.32M |
| Latest price (Nov 17, 2026) | $1.64 |
Key Dates
The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 6, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 38.35% over 52 weeks and trades 1.86% above its 50-day average.
| Beta (1Y) | 1.35 |
|---|---|
| 52-Week Change | -38.35% |
| 1-Month Change | +40.17% |
| 3-Month Change | -21.53% |
| 6-Month Change | +5.81% |
| 5-Year Change | -97.11% |
| Total Return (1Y) | -38.35% |
| Total Return (3Y CAGR) | -10.36% |
| Total Return (5Y CAGR) | -46.20% |
| Return vs SPY (1Y) | -51.49% |
| Max Drawdown (1Y) | -64.66% |
| Max Drawdown (3Y) | -89.84% |
| Sharpe Ratio (1Y) | -0.53 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $1.61 |
| 200-Day Average | $1.74 |
| 52-Week Range | $0.92 to $2.99 |
| RSI (14 Days) | 68.1 |
| Average Volume (20 Days) | 68.72K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.41x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.41x |
|---|---|
| Quick Ratio | 6.41x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -87.53% and return on assets is -74.25% over the last 12 months.
| Return on Equity (ROE) | -87.53% |
|---|---|
| Return on Assets (ROA) | -74.25% |
| ROIC (5Y Average) | -78.56% |
Scores
CMMB has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Operating Income | -$7.96M |
| Pretax Income | -$7.60M |
| Net Income | -$7.60M |
| Reported EPS (TTM) | -$2.81 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 84.77% of the $10.24M in total assets.
| Cash and Equivalents | $6.00M |
|---|---|
| Total Debt | $0 |
| Net Cash | $6.00M |
| Working Capital | $8.40M |
| Shareholder Equity | $8.68M |
| Total Assets | $10.24M |
| Total Liabilities | $1.55M |
Balance sheet as of Jun 30, 2026.
Cash Flow
| Capital Expenditures | $3.03K |
|---|---|
| FCF Per Share | -$3.44 |
Trailing 12 months through Jun 30, 2026.
Stock Splits
The last split was a 1-for-4 reverse split on Aug 26, 2025.
| Last Split Date | Aug 26, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:4 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CMMB
What is CMMB's market cap?
Chemomab Therapeutics Ltd DRC has a market cap of $12.31M. Its enterprise value, which adds debt and subtracts cash, is $6.32M.
How many shares of CMMB are outstanding?
Chemomab Therapeutics Ltd DRC has 8.00M shares outstanding. The count is up 38.13% from a year earlier.
Does CMMB pay a dividend?
No. Chemomab Therapeutics Ltd DRC does not pay a dividend.
How much debt does CMMB have?
Chemomab Therapeutics Ltd DRC has $0 of total debt and $6.00M of cash and equivalents, a net cash position of $6.00M.
CMMB pages: Overview, Charting, Earnings, Forecast, Statistics, Competitors